Litcius/Paper detail

Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial

Constantine S. Tam, Jennifer R. Brown, Brad S. Kahl, Paolo Ghia, Krzysztof Giannopoulos, Wojciech Jurczak, Martin Šimkovič, Mazyar Shadman, Anders Österborg, Luca Laurenti, Patricia Walker, Stephen Opat, Henry Chan, Hanna Ciepłuch, Richard Greil, Monica Tani, Marek Trněný, Danielle M. Brander, Ian W. Flinn, Sebastian Grosicki, Emma Verner, Alessandra Tedeschi, Jianyong Li, Tian Tian, Lei Zhou, Carol Marimpietri, Jason C. Paik, Aileen Cohen, Jane Huang, Tadeusz Robak, Peter Hillmen

2022The Lancet Oncology278 citationsDOIOpen Access PDF

Topics & Concepts

BendamustineMedicineRituximabChronic lymphocytic leukemiaInternal medicinePopulationProgression-free survivalClinical endpointOncologyLymphomaClinical trialChemotherapyLeukemiaEnvironmental healthChronic Lymphocytic Leukemia ResearchLymphoma Diagnosis and TreatmentPhagocytosis and Immune Regulation